Acer Therapeutics Inc

Acer Therapeutics — Investor Presentation (December 2017)

29 slides from Acer Therapeutics's investor presentation, Dec 11, 2017

  1. Slide 1: Developing Therapeutics for the Treatment of Serious Rare Diseases

    Developing Therapeutics for the Treatment of Serious Rare Diseases with Significant Unmet Medical Needs December 2017 NASDAQ: ACER Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Offering Summary

    Offering Summary Issuer Acer Therapeutics (NasdaqCM: ACER) Offering Size(1) Approximately $10.0M-$15.0M (100% Primary) Underwriters’ Option 15% (100% Primary) Use of Proceeds Acer intends to use the net proceeds from this offering to fund its research and development efforts, to seek regulatory appr

  4. Slide 4: Acer Corporate Overview

    Acer is a pharmaceutical company that acquires, develops and commercializes therapies for serious rare and ultra-rare diseases with significant unmet medical needs. Headquartered: Newton, MA Headcount: 8 Founded: December 2013 Public: September 2017 Cash and cash equivalents: $8.4M (as of September

  5. Slide 5: Management Team

    Chris Schelling, CEO and Founder 18 years of biotech/pharma strategic and orphan drug expertise Will Andrews, M.D., Chief Medical Officer 17 years in both Clinical Development and Medical Affairs in multiple therapeutic areas, with a focus on and extensive experience in rare diseases. Significant me

  6. Slide 6: Investment Highlights

    Investment Highlights Lead candidate (EDSIVO™) is a new chemical entity (NCE) for treatment of Vascular Ehlers-Danlos syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of potential launch ACER-001 for treatment of Urea Cycle Disorders (UCD)

  7. Slide 7: Clinical Pipeline and Key Regulatory Milestones

    Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 3 NDA Market EDSIVOTM (celiprolol) vEDS (COL3A1+) Improves hemodynamic stability; decreases vascular resistance ACER-001 (reformulated sodium phenylbutyrate) UCD Comparable to Buphenyl; taste-masked MSUD Inhibition of BCKD

  8. Slide 8: EDSIVO Overview

    Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and/or ruptures Median survival is 51 years of age Identified in over 2,000 patients in the U.S. Vascular Ehlers-Danlos

  9. Slide 9: Vascular Ehlers-Danlos syndrome (vEDS)

    Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Gastrointestinal Uterine Autosomal dominant (50%); spontaneous mutations (50%) Diagnosed by clinical symptom

  10. Slide 10: Physician quotes on vascular EDS

    “In vascular EDS the body lacks sufficient type III collagen, a molecule that contributes to the strength of the skin, intestines, uterus, and most importantly, the blood vessels.” “People with vascular EDS live with the knowledge that they will die from this condition.” “They are also told that the

  11. Slide 11: EDSIVO Unique Mechanism of Action

    Cardiology in Review 2017;25: 247–253 EDSIVO™ Unique Mechanism of Action EDSIVO™ has a unique pharmacological profile: Selective β1 and ⍺2 adrenergic receptor antagonist β2 and β3 adrenergic receptor agonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Void of blood

  12. Slide 12: Pivotal trial design

    Multicenter, prospective, randomized, open trial with blinded endpoint assessment Design: 9 sites: eight in France, one in Belgium Location: Inclusion criteria adapted Villefranche diagnostic criteria: 1 major criterion and 2 minor criteria, or 4 minor criteria needed for enrollment Eligibility: 53

  13. Slide 13: EDSIVO Statistically Significant Efficacy

    Results & Analysis: Trial stopped early for treatment benefit (mean follow-up 47 months) The primary endpoint (arterial dissection or rupture) affected 5 (20%) celiprolol patients and 14 (50%) controls (hazard ratio [HR] 0.36; p=0.04) Primary and secondary endpoints (intestinal or uterine rupture) a

  14. Slide 14: EDSIVO vEDS Patient Registry

    EDSIVO™ vEDS Patient Registry Paris (AP-HP) Registry PIs: Michael Frank, Xavier Jeunemaitre 144 patients enrolled in registry 100% of patients in registry have COL3A1 gene mutation >80% of patients on celiprolol Study Period: Jan. 2000 to Dec. ‘14 (for initial referral patients), followed until 2017

  15. Slide 15: EDSIVO Data Package

    EDSIVO™ Data Package Pivotal Clinical Trial n = 53 patients (62% COL3A1+) Statistically-significant improvement in 1º endpoint EFS (p=0.04) Paris Registry: n = 144 patients (100% COL3A1+) >80% patients on celiprolol Sanofi MHRA Dossier >13,000 pages (220 studies) Pharmacology, PK/PD, repro/tox, clin

  16. Slide 16: vEDS Market Sizing

    vEDS Market Sizing* vEDS patient population for basis of market sizing = 4,169 patients 2 instances of the EDS Dx Code 756.83 separated by ≥ 2 months Includes at least one other Dx or CPT code relevant to vEDS -AND- Excludes hypermobility syndrome * Based on sampling of phenotype, rather than genoty

  17. Slide 17: Accelerate Diagnosis

    Accelerate Diagnosis https://www.genetests.org/genes/?gene=COL3A1 * Based on sampling of phenotype, rather than genotype Facial Recognition Program Patients with vEDS have relatively similar / identifiable facial features Want a quick, cost-effective test to potentially help screen for vEDS patients

  18. Slide 18: vEDS Patient and Payer Demographics

    18 vEDS Patient and Payer Demographics

  19. Slide 19: EDSIVO Proposed Commercial Strategy

    EDSIVO™ Proposed Commercial Strategy EDSIVO™ Proposed Launch Plan* Identify vascular medicine specialists / cardiologists who: Can manage patients and their families Are familiar with orphan therapies Refer to CV surgeons Work closely with a team of specialists Will focus initially on cardiology/vas

  20. Slide 20: EDSIVO HEOR

    20 EDSIVO™ HEOR Precision Health Economics is developing a health economic (cost-consequence) model demonstrating the economic and clinical value of vEDS Centers of Excellence, and the potential impact of EDSIVO™ on patient outcomes These models will help quantify and communicate cost offsets associ

  21. Slide 21: EDSIVO Market Opportunity

    If approved, EDSIVO™ will be the only FDA-approved therapy to treat vEDS patients 2,000 to 5,000 vEDS patients in the U.S. Orphan pricing well supported by initial payer research, with additional validation from HEOR models Provide a robust patient assistance program (PAP) to help offset costs (so t

  22. Slide 22: ACER-001 Overview

    A group of metabolic genetic diseases that lead to toxic build-up of NH4+ Currently treated with Ravicti, Buphenyl, Ammonul, and a highly-restricted diet >2,000 patients with UCD in the U.S.; ~600 patients treated with sodium / glycerol phenylbutyrate Urea Cycle Disorders (UCD) A metabolic genetic d

  23. Slide 23: Urea Cycle Disorders (UCD)

    Urea cycle disorders are a group of genetic disorders caused by mutations that result in a deficiency of one of the six enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the blood stream The estimated incidence of urea cycle disorders is 1 in 8,500 births Treatment o

  24. Slide 24: Sodium phenylbutyrate lowers branched-chain amino acids

    In addition to lowering levels of ammonia in patients with urea cycle disorders (UCD), sodium phenylbutyrate (NaPB) also significantly reduces branched-chain amino acids (BCAAs)1 NaPB’s ability to lower leucine and other BCAAs could provide clinically-meaningful benefit in another genetic disease: M

  25. Slide 25: Maple Syrup Urine Disease (MSUD)

    MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of

  26. Slide 26: ACER-001 Taste-Masked, Immediate Release

    ACER-001 Taste-Masked, Immediate Release Mouth → Stomach Excellent protection for several minutes at mouth pH followed by rapid release at stomach pH Phenylbutyrate Formulations ACER-001 RAVICTI BUPHENYL Efficacy/Safety in UCD ✓ ✓ ✓ Efficacy/Safety in MSUD ✓ ✘ ✓ Palatability / Compliance ✓ ✓ ✘ Relat

  27. Slide 27: ACER-001 Market Opportunity

    Cannibalize existing sodium phenylbutyrate market share in UCD Taste-masked, immediate-release formulation Competitively priced Life cycle expansion opportunity in MSUD Barriers to entry: Filed formulation patent application (January 2016) Issued patent (US/EP) “Methods of modulation of branched cha

  28. Slide 28: Acer Financial Overview

    Acer Financial Overview Cash and cash equivalents: $8.4M (as of September 30, 2017) Pre-deal, expected to have sufficient funding through NDA filing for EDSIVO™ Capitalization at November 2017 6.5M shares of common stock 6.9M shares of common stock fully diluted* $28M invested to date through Novemb

  29. Slide 29: Acer Summary

    Acer Summary Lead candidate (EDSIVO™) is a new chemical entity (NCE) for treatment of Vascular Ehlers-Danlos syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of potential launch ACER-001 for treatment of Urea Cycle Disorders (UCD) and Maple

Acer Therapeutics — Investor Presentation (December 2017) on 6ix